📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! Tell us what works, what doesn't, and how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community. Please send your feedback to gateway@ukri.org by 11 August 2025.

Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). (2020)

First Author: Yiu ZZN

Attributed to: MICA: Psoriasis Stratification to Optimise Relevant Therapy (PSORT) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1111/bjd.18981

PubMed Identifier: 32124442

Publication URI: http://europepmc.org/abstract/MED/32124442

Type: Journal Article/Review

Volume: 183

Parent Publication: The British journal of dermatology

Issue: 2

ISSN: 0007-0963